Daily Briefing – June 11: Oracle sells off after strong Q4 but huge AI capex, CPI remains hot at +4.2%, oil rises on U.S.-Iran escalation, ECB and PPI in focus

The June 11, 2026 briefing starts with a cleaner but tougher market setup than yesterday: the May CPI is now confirmed by the BLS at +4.2% year-over-year, with core CPI at +2.9% and energy still the key pressure point. Oracle reported strong Q4 numbers after the close, but the stock sold off in after-hours trading because investors focused less on revenue growth and more on the enormous AI infrastructure bill: remaining performance obligations reached roughly $638 billion, while fiscal 2027 capex guidance moved toward as much as $95 billion. At the same time, U.S.-Iran tensions continue to drive the oil tape, with Brent trading near the mid-$90s as markets watch the Strait of Hormuz risk. Today’s macro checklist is heavy: U.S. PPI is scheduled for release, Europe is watching the ECB decision, and the 2026 World Cup opens in Mexico. The read for traders is simple: AI is still structural, but the market is now separating real backlog from free-cash-flow pressure, while inflation and oil keep rate-sensitive growth stocks under stress.

• ORCL— Oracle is now the key post-earnings AI read. Q4 revenue came in at about $19.18B, cloud infrastructure growth remained very strong, and remaining performance obligations reached roughly $638B. The problem: investors are worried about fiscal 2027 capex that could reach $95B and the financing/debt burden behind the AI buildout.AI Earnings
• May CPI— Official BLS data confirmed CPI-U at +4.2% year-over-year in May, up from +3.8% in April. Core CPI rose +2.9% year-over-year. The energy index was up +23.5% over the year, keeping the inflation/oil/Fed pressure trade alive.Macro / CPI
• PPI— U.S. Producer Price Index for May is today’s next inflation checkpoint. After April’s strong PPI reading, any fresh upside pressure would reinforce the message that inflation is not just a consumer-price story but also a pipeline-cost problem.Macro / PPI
• AAPL— Apple remains under pressure after the EU-related Siri AI overhang hit the consumer-AI narrative. The stock is now a test of whether mega-cap quality can absorb regulatory AI friction while the broader market reprices growth multiples.AI / Regulation
• NVDA— Nvidia is still the anchor of the AI trade, but Oracle’s capex reaction changes the tone: investors are no longer buying every AI backlog headline blindly. The new question is who earns durable returns from the infrastructure spend.AI Leader
• MRVL— Marvell remains active ahead of its S&P 500 inclusion before the June 22 open. The setup combines custom silicon, AI data-center exposure and potential benchmark/passive-flow demand.AI / Index
• FLEX— Flex also enters the S&P 500 before the June 22 open. The stock carries a separate index-flow angle while investors reassess the broader technology supply-chain complex.Index Flow
• AVGO— Broadcom remains a cleaner AI infrastructure read than many software names because investors can track demand through chips, networking and custom silicon. Still, the valuation filter is tightening across the whole AI basket.AI Infra
• AMD / INTC— AMD and Intel remain chip-breadth checks. A durable AI rebound needs more than Nvidia alone: second-line semis must stabilize if the tape wants to rebuild confidence.Chip Breadth
• Biotech M&A— Biotech deal flow remains one of the few constructive sector supports. The market continues to prefer differentiated assets, credible regulatory paths and balance sheets that can survive a tougher rates backdrop.Pharma M&A
• VRDN— Viridian remains a near-term biotech catalyst watch, with veligrotug under Priority Review and a June 30, 2026 PDUFA target date in thyroid eye disease.PDUFA Watch
• Parabilis Medicines IPO— The proposed large biotech IPO remains a useful sentiment check for the sector’s primary market. If demand holds despite inflation and oil pressure, it would be a constructive signal for higher-quality biotech issuance.Biotech IPO
• GILD / MRK— Gilead and Merck stay in focus after positive Phase 3 topline data for the once-weekly oral HIV combination islatravir/lenacapavir. Long-acting chronic-disease treatment remains a major pharma theme.HIV / Phase 3
• COGT / BBIO / VERA / CORT / CAPR— The FDA basket remains central in a selective tape. Catalyst timing, cash runway, label risk and possible dilution need to be read together, not as isolated headline trades.Biotech FDA
• Ponte Messina (Italy)— The corruption probe tied to the Sicily-mainland bridge project remains a major Italian political story after Rome prosecutors opened an investigation into a retired judge and two associates.Italy / Politics

• Iran-USA escalation— Oil remains the immediate market transmission channel. Reuters reported crude moved higher as traders digested renewed U.S.-Iran strikes and Strait of Hormuz risk. Any further disruption keeps inflation and margin pressure in the foreground.Geopolitics
• CPI: +4.2% confirmed— The BLS release confirmed the May CPI acceleration. For markets, the issue is not just one print: energy inflation, oil risk and sticky core pressure make near-term Fed relief much harder to price.Inflation
• Oil: still the first macro variable— Brent near the mid-$90s keeps the market defensive. If crude stabilizes, equities can breathe; if it spikes again, inflation expectations and yields become the dominant trade.Oil / Geo
• Bond yields— High CPI and oil risk keep pressure on the long end. This matters most for QQQ, SOXX, unprofitable growth, small caps and biotech names that rely on external capital.Rates
• AI: backlog is not enough anymore— Oracle showed the new market rule: backlog and cloud growth still matter, but free cash flow, debt, capex intensity and margin pressure now matter just as much.AI Valuation
• ECB day— European markets opened cautiously higher while investors waited for the ECB decision and watched Middle East tensions. A more hawkish ECB tone would add another layer of pressure to global rate-sensitive assets.Europe / ECB
• PPI day— The May PPI release is the next test after CPI. If producer prices stay hot, the market will treat inflation as a broader cost-pipeline problem rather than a one-off energy shock.Inflation
• Tariffs and trade— Trade policy remains a background risk for margins and supply chains. In a high-CPI tape, tariff headlines can be priced faster because the market is already sensitive to cost pass-through.Trade
• Biotech selectivity— M&A and catalyst stocks can still work, but broad sector risk appetite remains fragile when yields rise. Cash runway, dilution risk and credible clinical/regulatory timelines matter more than hype.Biotech
• World Cup 2026— The tournament opens today in Mexico, creating a global consumer, advertising, media and travel-spend theme. It is not a single-stock catalyst by itself, but it can affect travel, betting, media and payment-flow narratives.Sports / Macro